Quinine‑Related Cardiotoxicity

Overview

Quinine‑related cardiotoxicity refers to abnormal heart function that occurs as an adverse reaction to quinine, a bitter alkaloid historically used to treat malaria and, more recently, to relieve leg‑cramp symptoms. While quinine is generally safe at prescribed doses, it can cause serious cardiac effects—including arrhythmias, QT‑interval prolongation, myocarditis, and heart failure—in a subset of patients.

Who is affected? Cardiotoxic reactions have been reported in adults of both sexes, but they are most commonly documented in:

• Individuals taking quinine for off‑label “muscle cramp” therapy.
• Patients with pre‑existing cardiac disease (e.g., congestive heart failure, prior myocardial infarction).
• Elderly patients (>65 years) who have reduced renal clearance.

Prevalence data are limited because quinine‑induced cardiac events are rare and often under‑reported. The U.S. FDA’s Adverse Event Reporting System (FAERS) recorded ≈150 cases of serious cardiac events related to quinine from 2000‑2022, representing <0.01 % of all quinine prescriptions. However, in regions where quinine is used widely for malaria (sub‑Saharan Africa, South‑East Asia), the incidence of cardiotoxicity is estimated at 0.1 %–0.3 % of treated patients ^[1][2].

Symptoms

Cardiac toxicity can present with a wide spectrum of signs and symptoms, ranging from subtle palpitations to life‑threatening arrhythmias. Below is a comprehensive list:

• Palpitations – sensation of a racing, fluttering, or skipped heartbeat.
• Chest discomfort or pain – may mimic angina.
• Syncope or near‑syncope – fainting or feeling about to faint.
• Dizziness or light‑headedness – especially on standing.
• Shortness of breath (dyspnea) – can occur at rest or with exertion.
• Peripheral edema – swelling of ankles/feet indicating heart failure.
• Fatigue or decreased exercise tolerance.
• Palmar or plantar erythema and pruritus – part of the quinine syndrome that may accompany cardiac toxicity.
• QT‑interval prolongation signs – torsades de pointes (a specific type of ventricular tachycardia) may present with sudden loss of consciousness.
• Myocarditis‑type symptoms – fever, myalgias, and elevated cardiac enzymes.

Causes and Risk Factors

Mechanism of Cardiotoxicity

Quinine interferes with cardiac electrophysiology by blocking the rapid component of the delayed rectifier potassium current (I_Kr), leading to prolonged repolarization and QT‑interval lengthening. High plasma concentrations also cause direct myocardial depression, calcium‑channel inhibition, and in rare cases immune‑mediated myocarditis.

Primary Causes

• Therapeutic overdose – accidental ingestion of doses >600 mg/day (the usual adult dose for malaria) or intentional misuse for cramp relief.
• Drug interactions – co‑administration with other QT‑prolonging agents (e.g., macrolide antibiotics, fluoroquinolones, anti‑psychotics) magnifies risk.
• Renal or hepatic impairment – reduced clearance leads to higher systemic quinine levels.
• Genetic predisposition – polymorphisms in the CYP3A4/5 enzymes affect metabolism.

Risk Factors

• Age >65 years.
• Pre‑existing structural heart disease (e.g., left‑ventricular hypertrophy, prior MI).
• Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia).
• Concurrent use of other QT‑prolonging drugs.
• Severe renal insufficiency (eGFR <30 mL/min/1.73 m²) or hepatic cirrhosis.
• History of congenital long QT syndrome.

Diagnosis

Timely identification relies on a combination of clinical suspicion, detailed medication history, and targeted investigations.

Step‑by‑Step Approach

1. History & Physical Examination – Document quinine dose, duration, and any recent changes. Look for signs of arrhythmia (irregular pulse) or heart failure (jugular venous distension, crackles).
2. Electrocardiogram (ECG) – The cornerstone test. Findings may include:
   • QTc prolongation (>460 ms in women, >450 ms in men).
   • T‑wave abnormalities.
   • Premature ventricular complexes or sustained ventricular tachycardia.
3. Laboratory Studies
   • Serum quinine level (if available) – >10 µg/mL generally correlates with toxicity.
   • Electrolytes, renal and hepatic panels.
   • Cardiac biomarkers (troponin, CK‑MB) – elevated in myocarditis or myocardial injury.
4. Imaging
   • Transthoracic echocardiogram (TTE) – assesses ventricular function and detects wall motion abnormalities.
   • Cardiac MRI (CMR) – useful if myocarditis suspected; shows late gadolinium enhancement.
5. Holter Monitoring or Event Recorder – 24‑48 h monitoring to capture intermittent arrhythmias.
6. Drug Interaction Review – Pharmacist‑led assessment of concurrent QT‑prolonging agents.

Diagnosis is confirmed when a temporal relationship exists between quinine exposure and cardiac abnormality, and other causes have been excluded.

Treatment Options

Treatment aims to remove the offending agent, stabilize cardiac rhythm, and address any underlying organ dysfunction.

Immediate Measures

• Discontinue quinine – Stop the drug immediately; most toxicity resolves once serum levels fall.
• Electrolyte Repletion – Aggressive correction of potassium (target >4.5 mmol/L), magnesium (>2.0 mg/dL), and calcium if low.
• IV Magnesium Sulfate – 2 g over 15 min for QT prolongation or torsades de pointes (per AHA guidelines).

Anti‑arrhythmic Management

1. Overdrive Pacing – Temporary transvenous pacing if symptomatic bradycardia or high‑grade AV block develops.
2. Pharmacologic Therapy
   • Lidocaine or mexiletine for ventricular ectopy.
   • Beta‑blockers (e.g., metoprolol) for supraventricular tachycardia, provided no contraindication.
   • Avoid class IA and III anti‑arrhythmics that further prolong QT.
3. Defibrillation – Immediate unsynchronised shock for cardiac arrest.

Supportive Care

• Oxygen supplementation if SpO₂ <94 %.
• Intravenous fluids cautiously administered in heart‑failure patients.
• Mechanical ventilation for severe respiratory compromise.

Long‑Term Management

• Cardiology Follow‑up – Repeat ECG and echocardiogram 1–2 weeks after cessation.
• Medication Review – Permanent avoidance of quinine and any other QT‑prolonging drugs.
• Implantable Cardioverter‑Defibrillator (ICD) – Considered in patients with persistent high‑risk arrhythmias despite drug withdrawal.

Living with Quinine‑Related Cardiotoxicity

Patients who have experienced quinine‑induced cardiac effects can lead normal lives with proper monitoring and lifestyle adjustments.

• Medication Diary – Keep a written record of all prescribed and over‑the‑counter drugs; share it with every healthcare provider.
• Regular Monitoring – Schedule ECGs every 3–6 months, especially if you have other risk factors.
• Electrolyte Balance – Maintain adequate dietary potassium (bananas, potatoes) and magnesium (nuts, leafy greens).
• Avoid Stimulants – Limit caffeine, nicotine, and illicit stimulants that can provoke arrhythmias.
• Physical Activity – Engage in moderate aerobic exercise (e.g., brisk walking 30 min most days) unless your cardiologist advises restrictions.
• Vaccinations – Influenza and COVID‑19 vaccines reduce the risk of infections that could stress the heart.
• Emergency Plan – Carry a card or medical alert bracelet stating “Quinine allergy – risk of cardiac arrhythmia.”

Prevention

Because quinine is rarely needed in the United States and many countries now favor safer alternatives, prevention focuses on prudent prescribing and patient education.

• Reserve quinine for malaria or well‑documented severe leg‑cramp refractory cases.
• Screen for cardiac history and electrolyte abnormalities before prescribing.
• Use the lowest effective dose (≤200 mg three times daily for malaria) and restrict treatment duration.
• Check for drug interactions using electronic prescribing tools.
• Educate patients about warning signs (palpitations, dizziness, syncope) and instruct them to stop the drug and seek care immediately.
• Consider alternative therapies for leg cramps—stretching, hydration, magnesium supplementation, or low‑dose gabapentin (per AHA recommendations).

Complications

If untreated, quinine‑related cardiotoxicity can progress to serious, potentially irreversible conditions:

• Torsades de pointes → sudden cardiac death.
• Persistent ventricular tachycardia or fibrillation → requires emergency defibrillation.
• Acute heart failure – reduced ejection fraction, pulmonary edema.
• Myocarditis – may lead to chronic dilated cardiomyopathy.
• Thromboembolic events – atrial fibrillation increases stroke risk.
• Renal dysfunction – secondary to low cardiac output.

When to Seek Emergency Care

References

1. Mayo Clinic. Quinine: Uses, Side Effects, and Interactions. Updated 2023.
2. World Health Organization. Guidelines for the Treatment of Uncomplicated Malaria. 2020.
3. U.S. Food & Drug Administration. FAERS Reports on Quinine Cardiac Events. accessed May 2026.
4. American Heart Association. 2023 AHA/ACC/HRS Guideline for Management of Ventricular Arrhythmias.
5. Cleveland Clinic. Quinine: Side Effects and Risks. 2024.
6. National Institutes of Health, National Library of Medicine. Quinine‑induced QT prolongation and torsades de pointes: A systematic review. *J Clin Pharmacol*. 2023.